Aquaculture Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Attenuated Live Vaccines, Inactivated Vaccines, Subunit Vaccines, DNA Vaccines, Recombinant Vaccines), By Route of Administration (Oral, Injected, Immersion & Spray), By Application (Bacterial, Viral, Parasitic), By Region and Competition, 2020-2030F

Market Overview

The Global Aquaculture Vaccines Market, valued at USD 399.49 Million in 2024, is projected to experience a CAGR of 7.95% to reach USD 632.18 Million by 2030. Aquaculture vaccines are biological preparations administered to farmed aquatic animals to prevent and control infectious diseases, thereby enhancing animal health and production efficiency. The global aquaculture vaccines market is primarily driven by the escalating demand for aquatic food products, leading to intensified farming practices and a subsequent rise in disease prevalence. Concurrently, an increased industry focus on sustainable aquaculture and proactive disease management strategies, rather than relying solely on antibiotics, supports market expansion. According to the Food and Agriculture Organization of the United Nations (FAO), in 2022, global aquaculture production reached 130.9 million tonnes, valued at USD 312.8 billion.

A significant challenge impeding market expansion involves the substantial research and development costs associated with developing new vaccines. This is exacerbated by the wide biological diversity of aquaculture species and their numerous pathogens, alongside complex and varying regulatory approval pathways across different geographical markets.

Key Market Drivers

The aquaculture vaccines market expansion is significantly influenced by the high prevalence of infectious diseases within aquaculture production systems. Intensive farming practices, necessary to meet increasing global demand for aquatic food products, create environments where pathogens spread rapidly, leading to substantial economic losses and threatening food security. These outbreaks necessitate effective prophylactic solutions to maintain animal health and production stability. According to the Food and Agriculture Organization of the United Nations, in its 2024 report on The State of World Fisheries and Aquaculture, aquaculture production of aquatic animals reached 94.4 million tonnes in 2022, underscoring the immense scale of aquatic animal farming that is highly vulnerable to devastating disease impacts. The consistent threat posed by various bacterial, viral, and parasitic agents highlights the critical role of vaccines in preventing widespread morbidity and mortality.

A second compelling driver for market growth stems from growing concerns regarding antimicrobial resistance. The widespread use of antibiotics in aquaculture has contributed to resistant bacterial strains, posing risks to both animal and human health. Consequently, there is an escalating imperative within the industry and regulatory bodies to reduce reliance on antimicrobials. According to the World Organisation for Animal Health, November 2024, in its publication "Towards a Healthier Future for All", the European Union in 2022 achieved half of its target to reduce overall sales of antimicrobials for farmed animals and aquaculture by 50% before 2030. This regulatory pressure and industry commitment to biosecurity directly stimulate demand for innovative vaccine solutions. Furthermore, significant investments reflect this market trajectory, for instance, according to Zoetis, in September 2024, it invested USD 45 million to expand its aquaculture vaccine manufacturing facility in Norway, increasing production capacity by 60%.

Download Free Sample Report

Key Market Challenges

A significant challenge impeding the growth of the global aquaculture vaccines market stems from the substantial research and development costs required for new vaccine creation. This financial burden is notably intensified by the extensive biological diversity among aquaculture species and the multitude of pathogens they encounter. Developing effective vaccines for a wide array of species, each with unique immunological responses, demands considerable resources and specialized expertise.

Furthermore, the complex and varied regulatory approval pathways across different geographical markets exacerbate these costs, lengthening development timelines and increasing the financial outlay before a product can reach commercialization. Such high investment requirements deter smaller companies from entering the market and limit the number of new vaccines introduced, particularly for less commercially viable species or regions. According to the Scottish Government's Aquaculture Innovation Fund, in 2024, GBP 6 million was invested in health management research, directly supporting the development of advanced vaccination technologies. This illustrates the significant financial commitment necessary, which directly hinders broader innovation and the timely availability of essential preventive health solutions for the aquaculture industry.

Key Market Trends

Geographic expansion into emerging aquaculture markets represents a significant trend, driven by the increasing global demand for aquatic protein and the potential for aquaculture development in previously underserved regions. These emerging markets, particularly in Africa, offer substantial growth opportunities due to rising populations, improving economic conditions, and government initiatives to enhance food security. For instance, according to the Food and Agriculture Organization of the United Nations in its 2024 report, aquaculture production in Africa has demonstrated the highest growth rate worldwide since 2000, expanding by 455 percent. This rapid development necessitates robust health management solutions, including vaccines, adapted to local species and prevalent pathogens. In a notable move to capitalize on this expanding demand, Fischer Medical Ventures Ltd announced in July 2024 that it teamed up with Bio Angle Vacs Sdn Bhd to introduce innovative vaccines to India, alongside plans to build a production facility in India to supply local and Middle Eastern markets. Such partnerships are crucial for tailoring vaccine solutions to regional needs and establishing distribution networks in these burgeoning aquaculture landscapes.

Industry consolidation and strategic partnerships are profoundly shaping the competitive landscape of the global aquaculture vaccines market. Larger animal health companies are increasingly acquiring smaller, specialized vaccine developers or forming alliances to broaden their product portfolios, enhance research and development capabilities, and gain access to new technologies or markets. This trend is further evidenced by investment patterns; The Fish Site reported in January 2025 that the total number of investment deals in aquaculture startups increased by 15 percent, from 61 in 2023 to 70 in 2024. A prominent example of this consolidation occurred when Merck Animal Health announced in February 2024 its agreement to acquire the aquatic-focused business of Elanco Animal Health for USD 1.3 billion, with the acquisition completed in July 2024. This strategic acquisition bolstered Merck Animal Health's presence in the aqua industry by integrating Elanco's portfolio of medicines and vaccines, including manufacturing facilities in Vietnam and Canada, and a research facility in Chile. Such transactions allow companies to achieve economies of scale, streamline operations, and deliver more comprehensive health solutions to aquaculture producers globally.

Segmental Insights

The key segmental insight for the Global Aquaculture Vaccines Market reveals recombinant vaccines as the fastest-growing segment. This accelerated growth is primarily driven by their enhanced safety profile and superior ability to elicit a robust immune response, closely mimicking natural immunity in aquatic species. Unlike traditional vaccine types, recombinant vaccines can be precisely engineered to target specific pathogen components, leading to improved efficacy against a broader spectrum of diseases and addressing concerns related to antibiotic resistance. Furthermore, advancements in biotechnology enable more efficient and scalable production processes, supporting the increasing demand for effective disease prevention strategies in aquaculture worldwide. This segment's development aligns with the industry's continuous efforts to ensure sustainable production and safeguard aquatic animal health.

Regional Insights

Asia Pacific leads the global aquaculture vaccines market due to its unparalleled dominance in aquaculture production. The region, particularly nations like China, India, Indonesia, and Vietnam, accounts for the vast majority of worldwide aquaculture output, driven by significant seafood consumption and available water resources. This extensive farming activity, often characterized by intensive practices, inherently leads to a higher prevalence of infectious diseases among aquatic species, thereby necessitating robust preventative measures such as vaccination. Furthermore, supportive government initiatives and regulatory bodies, including those aligned with the Food and Agriculture Organization of the United Nations, increasingly advocate for reduced antibiotic use in aquaculture to combat antimicrobial resistance, thus accelerating the adoption of vaccines for sustainable fish health management.

Recent Developments

• In March 2025, AquaTactics, a division of Bimeda, announced its entry into the autogenous fish vaccine sector following USDA approval. This enabled the company to provide customized vaccine solutions to address specific disease challenges faced by aquaculture operations across the United States. The production and safety testing for these autogenous vaccines were conducted at Bimeda’s established vaccine facility in Texas. This expansion marked a significant step in offering tailored, high-quality fish vaccines to veterinarians and fish health professionals, thereby supporting improved health and productivity within the U.S. aquaculture industry.

• In July 2024, Uvaxx, a subsidiary of Barramundi Group, and the Agency for Science, Technology and Research (A*STAR) announced the development of a novel epitope-based vaccine. This breakthrough research targeted the Scale Drop Disease Virus (SDDV) in Asian seabass, a viral infection capable of causing high mortality rates in farmed populations. The new vaccine, designed to trigger specific immune responses using pathogen proteins, demonstrated an efficacy rate of 75%. This innovative approach aims to offer a more targeted and safer alternative to conventional vaccines, preparing for its integration into routine fish farm operations.

• In July 2024, Fischer Medical Ventures Ltd partnered with Bio Angle Vacs Sdn Bhd to introduce advanced vaccines into the Indian market. This strategic collaboration aimed to significantly reduce mortality rates in both livestock and aquaculture species within India. Bio Angle Vacs, a biotechnology company based in Malaysia, specializes in innovative vaccine development and delivery. The partnership included the launch of VIVAC aqua-feed, a vaccine protecting marine fish against various *Vibrio* bacteria, and AQUABOOSTER, an oral vaccine effective against multiple harmful bacteria in freshwater fish, enhancing disease prevention efforts.

• In April 2024, Mowi Scotland and Ridgeway Biologicals Ltd collaborated to implement a new vaccine strategy for Atlantic salmon. This partnership focused on protecting salmon from *Yersinia ruckeri*, the causative agent of enteric red mouth disease (ERM), which has caused significant mortalities in Scottish salmon farms. Building on successful prior collaborations, the new strategy involved both a dip vaccination during freshwater stages and an intraperitoneal injection before transfer to sea. This initiative aimed to enhance fish health, improve welfare, and reduce the reliance on antibiotics in salmon aquaculture.

Key Market Players

• Zoetis Inc.
• Phibro Animal Health Corporation
• Elanco Animal Health Incorporated
• Merck KGaA
• KBNP Inc.
• UNILINE GROUP FOR VETERINARY EQUIPMENT
• Kyoto Biken Laboratories, Inc.
• Nisseiken Co., Ltd.
• Vaxxinova International BV
• HIPRA SA

Report Scope:

In this report, the Global Aquaculture Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Aquaculture Vaccines Market, By Product:

o   Attenuated Live Vaccines

o   Inactivated Vaccines

o   Subunit Vaccines

o   DNA Vaccines

o   Recombinant Vaccines

• Aquaculture Vaccines Market, By Route of Administration:

o   Oral

o   Injected

o   Immersion & Spray

• Aquaculture Vaccines Market, By Application:

o   Bacterial

o   Viral

o   Parasitic

• Aquaculture Vaccines Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Aquaculture Vaccines Market.

Available Customizations:

Global Aquaculture Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Aquaculture Vaccines Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]